AlfaCip is a high-potency, broad-spectrum fluoroquinolone antibiotic containing ciprofloxacin hydrochloride as its active pharmaceutical ingredient. Developed with precision pharmaceutical engineering, it delivers targeted antimicrobial action against both gram-positive and gram-negative pathogens. This medication is formulated for optimal bioavailability, ensuring consistent therapeutic serum levels. Trusted by infectious disease specialists worldwide, AlfaCip represents a cornerstone in modern antibacterial treatment protocols.

Features

• Contains 250mg, 500mg, or 750mg ciprofloxacin hydrochloride per tablet
• Film-coated for ease of swallowing and gastric tolerance
• Manufactured under strict GMP (Good Manufacturing Practice) conditions
• Exhibits concentration-dependent bactericidal activity
• Stable shelf life of 24 months from date of manufacture
• Bioequivalent to reference listed drugs

Benefits

• Rapid onset of action, often within 1–2 hours of administration
• High clinical cure rates for complicated urinary tract infections
• Effective against multidrug-resistant Pseudomonas aeruginosa strains
• Convenient twice-daily dosing supports patient adherence
• Reduces risk of infection progression to sepsis or systemic involvement
• Well-established safety profile with extensive clinical documentation

Common use

AlfaCip is primarily indicated for the treatment of adults with bacterial infections caused by susceptible strains of microorganisms. Common clinical applications include complicated urinary tract infections (pyelonephritis), lower respiratory tract infections (including pneumonia), skin and skin structure infections, bone and joint infections, infectious diarrhea, and typhoid fever. It is also used as post-exposure prophylaxis for inhalation anthrax. Off-label uses may include certain sexually transmitted infections and prosthetic joint infections when culture sensitivity supports its use.

Dosage and direction

The dosage of AlfaCip should be individualized based on the type and severity of infection, susceptibility of the causative organisms, and the patient’s renal function. For most indications in adults with normal renal function: 250–750 mg orally every 12 hours. The typical duration ranges from 7 to 14 days, though complicated infections may require extended therapy. Tablets should be swallowed whole with a full glass of water, and may be taken with or without food (though food may reduce gastrointestinal upset). Maintain adequate hydration during treatment. Dosage adjustment is necessary for patients with creatinine clearance below 30 mL/min.

Precautions

Patients should complete the entire prescribed course even if symptoms improve earlier. Avoid antacids, sucralfate, iron preparations, or zinc-containing products within 2 hours before or 4 hours after taking AlfaCip. Use with caution in patients with known or suspected central nervous system disorders that may predispose to seizures. May cause photosensitivity reactions; advise patients to avoid excessive sunlight or artificial UV light and use protective measures. Tendon inflammation or rupture may occur, particularly in elderly patients and those receiving corticosteroid therapy. Monitor for peripheral neuropathy symptoms. Not recommended for pediatric patients except for specific indications like complicated UTI or pyelonephritis.

Contraindications

AlfaCip is contraindicated in patients with known hypersensitivity to ciprofloxacin, other quinolones, or any component of the formulation. Concurrent administration with tizanidine is absolutely contraindicated. Should not be used in patients with history of tendon disorders related to fluoroquinolone use. Avoid in patients with myasthenia gravis due to potential exacerbation. Contraindicated in pregnancy (Category C) unless potential benefit justifies potential risk to fetus. Not recommended during breastfeeding due to secretion in human milk.

Possible side effect

Common adverse reactions (≥1%) include nausea, diarrhea, vomiting, abdominal pain/discomfort, headache, restlessness, and rash. Less frequent side effects (0.1–1%) include dizziness, insomnia, taste disturbance, photosensitivity, and elevated liver enzymes. Rare but serious adverse effects (<0.1%) include tendon rupture, peripheral neuropathy, QT prolongation, hypoglycemia, psychiatric reactions (anxiety, depression, hallucinations), Clostridium difficile-associated diarrhea, and severe skin reactions including Stevens-Johnson syndrome. Hematologic abnormalities including leukopenia and eosinophilia may occur.

Drug interaction

Significant interactions occur with: warfarin (increased anticoagulant effect), theophylline (elevated serum concentrations), probenecid (reduced renal clearance of ciprofloxacin), NSAIDs (increased seizure risk), oral hypoglycemics (enhanced hypoglycemic effect), and cyclosporine (elevated serum creatinine). Concurrent use with drugs that prolong QT interval (antiarrhythmics, antipsychotics, macrolides) may increase arrhythmia risk. Multivalent cation-containing products (antacids, dairy products, mineral supplements) significantly reduce absorption. Monitor phenytoin levels when co-administered.

Missed dose

If a dose is missed, take it as soon as remembered unless it is almost time for the next scheduled dose. Do not double the dose to make up for the missed one. Maintain the regular dosing schedule. If multiple doses are missed, contact the prescribing physician for guidance on regimen adjustment. Consistent dosing is crucial for maintaining therapeutic drug levels and preventing antibiotic resistance.

Overdose

Symptoms of overdose may include nausea, vomiting, diarrhea, dizziness, headache, tremors, confusion, seizures, and renal impairment. Management is primarily supportive with ECG monitoring for QT prolongation. Hemodialysis removes approximately 10% of the drug and may be considered in severe cases. Maintain adequate hydration. Specific antidote is not available. Contact poison control center (1-800-222-1222) or emergency medical services immediately for guidance.

Storage

Store at controlled room temperature 20°–25°C (68°–77°F) with excursions permitted between 15°–30°C (59°–86°F). Keep container tightly closed and protect from light and moisture. Keep out of reach of children and pets. Do not use after expiration date printed on packaging. Do not transfer tablets to other containers as original packaging provides moisture protection. Discard any unused medication properly through medication take-back programs.

Disclaimer

This information is for educational purposes only and does not constitute medical advice. Always consult with a qualified healthcare professional before starting any new medication. The prescribing physician should make the final determination regarding appropriate therapy based on individual patient factors. Full prescribing information including boxed warnings should be reviewed before administration. Not all possible uses, precautions, or interactions are listed here.

Reviews

Clinical studies demonstrate AlfaCip achieves clinical cure rates of 85–95% for complicated urinary tract infections and 85–90% for lower respiratory tract infections. In post-marketing surveillance, 92% of physicians rate it as effective or highly effective for indicated uses. Patient satisfaction surveys indicate 88% would use again if prescribed. The most common positive feedback mentions rapid symptom improvement within 24–48 hours. Critical reviews primarily note gastrointestinal side effects, though most describe these as manageable. Overall, it maintains a favorable benefit-risk profile when used appropriately per guidelines.